The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ARDS - Acute lung injury
Pulmonary toxicity may stem from the combination of brentuximab vedotin with bleomycin or gemcitabine. Non-bleomycin containing drug regimens may not induce pulmonary toxicity (PMID 24239220)
Publications
Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.
British journal of haematology 2018 10;183;251-256 — 2018 10 — 251-256
A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Expert opinion on drug safety 2016 Jun;15;875-82 — 2016 Jun — 875-82
Brentuximab vedotin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jan 01;19;22-7 — 2013 Jan 01 — 22-7